SCHEMBL19682795

SCHEMBL19682795

CC(Br)c1cccc2c1C(C)CO2

nearest known ligand 0.33

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MAP3K14 Q99558 1/20 0.33
P2RX7 Q99572 1/20 0.33
BCHE P06276 1/20 0.30
ACHE P22303 1/20 0.30
CES1 P23141 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8311621 0.86 GABRA1 (0.36) MAP3K14BCHEACHECES1
SCHEMBL22507751 0.74 ALOX5 (0.33) MAP3K14
SCHEMBL20889375 0.74 ALOX5 (0.33) MAP3K14
SCHEMBL19682600 0.74 ALOX5 (0.33) MAP3K14
SCHEMBL19682598 0.74 ALOX5 (0.33) MAP3K14
SCHEMBL13592845 0.73 MAP3K14 (0.53) MAP3K14BCHEACHECES1
SCHEMBL30456278 0.72 CYP19A1 (0.38) MAP3K14BCHEACHECES1
SCHEMBL2047603 0.72 MAP3K14 (0.40) MAP3K14BCHEACHECES1
SCHEMBL2479116 0.72 CHRNB4 (0.36) MAP3K14BCHEACHECES1
SCHEMBL8305953 0.69 MAP3K14 (0.34) MAP3K14BCHEACHECES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10889555-B2 Sulfonamide compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-01-12 US disclosed
US-20200405697-A1 Antitumor Agent TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-31 US disclosed
US-20200399235-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-24 US disclosed
EP-3718545-A1 ANTITUMOR AGENT Taiho Pharmaceutical Co., Ltd. (JP) 2020-10-07 EP disclosed
US-20200157066-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-05-21 US disclosed
EP-3466934-A1 SULFONAMIDE COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2019-04-10 EP disclosed
WO-2017209155-A1 SULFONAMIDE COMPOUND OR SALT THEREOF 大鵬薬品工業株式会社 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399235-A1 Sulfonamide Compound or Salt Thereof RNASEH1, SNRPA1, RRM2 MAP3K14 3138/4885P2RX7 3672/4885BCHE 4531/4885
US-20200157066-A1 Sulfonamide Compound or Salt Thereof RNASEH1, SNRPA1, RRM2 MAP3K14 3138/4885P2RX7 3672/4885BCHE 4531/4885
US-10889555-B2 Sulfonamide compound or salt thereof RNASEH1, SNRPA1, RRM2 MAP3K14 3138/4885P2RX7 3672/4885BCHE 4531/4885
US-20200405697-A1 Antitumor Agent HNRNPR, RRM2, RRM2B MAP3K14 4125/4885P2RX7 3886/4885BCHE 4649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.